David Bupp also said five years ago that he would be able to file Riggs without a phase 3 based on data that he already had.
He also said that he could get Lymphoseek approved based on one successful phase 3 trial but the stock went up when he announced that he would do a second phase 3 trial.
Dutton received their info from David Bupp the former CFO.